WRF
ENZY

Waddell & Reed Financial’s Enzymotec Ltd ENZY Stock Holding History

Waddell & Reed Financial’s Portfolio ENZY Stock Details ENZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-55,000
Closed -$1.21M – 578
2014
Q1 		$1.21M Buy
+55,000
New +$1.46M ﹤0.01% 535

Other funds holding ENZY

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MCM
Matterhorn Capital Management San Antonio, Texas $151M AUM 14.72% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.76% 1-Year Est. Return
MACM
March Altus Capital Management Greenwich, Connecticut $16M AUM 18.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Waddell & Reed Financial's ENZY Position: Q2 2014 in Review

Waddell & Reed Financial sold out of Enzymotec Ltd (ENZY) in Q2 2014, closing a stake of 55,000 shares — an estimated $1.21M sold.

Waddell & Reed Financial first reported a position in ENZY in Q1 2014 and held it in 1 quarter. The position peaked at $1.21M in Q1 2014. 25 funds tracked by Wall St. Rank hold ENZY as of Q2 2014.

  • Waddell & Reed Financial reported no remaining Enzymotec Ltd position as of Q2 2014 after selling out during the quarter.
  • Waddell & Reed Financial sold 55,000 Enzymotec Ltd shares in Q2 2014, an estimated $1.21M.
  • Waddell & Reed Financial first reported a position in Enzymotec Ltd in Q1 2014 and held it in 1 quarter.
  • Waddell & Reed Financial's Enzymotec Ltd position peaked at $1.21M in Q1 2014.
  • 25 funds tracked by Wall St. Rank held Enzymotec Ltd as of Q2 2014.

Based on Waddell & Reed Financial's 13F filing for Q2 2014, filed 14 Aug 2014.